Florida Senate - 2015                CS for CS for CS for SB 614
       
       
        
       By the Committees on Rules; Regulated Industries; and Health
       Policy; and Senator Grimsley
       
       
       
       
       595-04422-15                                           2015614c3
    1                        A bill to be entitled                      
    2         An act relating to health care; amending s. 110.12315,
    3         F.S.; expanding the categories of persons who may
    4         prescribe brand name drugs under the prescription drug
    5         program when medically necessary; amending ss.
    6         310.071, 310.073, and 310.081, F.S.; exempting
    7         controlled substances prescribed by an advanced
    8         registered nurse practitioner or a physician assistant
    9         from the disqualifications for certification or
   10         licensure, and for continued certification or
   11         licensure, as a deputy pilot or state pilot; repealing
   12         s. 383.336, F.S., relating to provider hospitals,
   13         practice parameters, and peer review boards; amending
   14         s. 395.1051, F.S.; requiring a hospital to provide
   15         specified advance notice to certain obstetrical
   16         physicians before it closes its obstetrical department
   17         or ceases to provide obstetrical services; amending s.
   18         409.967, F.S.; requiring a Medicaid managed care plan
   19         to allow a prescribing provider to request an override
   20         of a restriction on the use of medication imposed
   21         through a step-therapy or fail-first protocol;
   22         requiring the plan to grant such override within a
   23         specified timeframe under certain circumstances;
   24         prohibiting the duration of a step-therapy or fail
   25         first protocol from exceeding the time period
   26         specified by the prescribing provider; providing that
   27         an override is not required under certain
   28         circumstances; amending s. 456.072, F.S.; applying
   29         existing penalties for violations relating to the
   30         prescribing or dispensing of controlled substances by
   31         an advanced registered nurse practitioner; amending s.
   32         456.44, F.S.; deleting an obsolete date; requiring
   33         advanced registered nurse practitioners and physician
   34         assistants who prescribe controlled substances for
   35         certain pain to make a certain designation, comply
   36         with registration requirements, and follow specified
   37         standards of practice; providing applicability;
   38         amending s. 458.326, F.S.; defining the term
   39         “interventional pain medicine”; restricting the
   40         practice of interventional pain medicine to specified
   41         circumstances; amending ss. 458.3265 and 459.0137,
   42         F.S.; limiting the authority to prescribe a controlled
   43         substance in a pain-management clinic only to a
   44         physician licensed under ch. 458 or ch. 459, F.S.;
   45         amending s. 458.347, F.S.; revising the required
   46         continuing education requirements for a physician
   47         assistant; requiring that a specified formulary limit
   48         the prescription of certain controlled substances by
   49         physician assistants as of a specified date; amending
   50         s. 464.003, F.S.; redefining the term “advanced or
   51         specialized nursing practice”; deleting the joint
   52         committee established in the definition; amending s.
   53         464.012, F.S.; requiring the Board of Nursing to
   54         establish a committee to recommend a formulary of
   55         controlled substances that may not be prescribed, or
   56         may be prescribed only on a limited basis, by an
   57         advanced registered nurse practitioner; specifying the
   58         membership of the committee; providing parameters for
   59         the formulary; requiring that any formulary be adopted
   60         by board rule; specifying the process for amending the
   61         formulary and imposing a burden of proof; limiting the
   62         formulary’s application in certain instances;
   63         requiring the board to adopt the committee’s initial
   64         recommendations by a specified date; authorizing an
   65         advanced registered nurse practitioner to prescribe,
   66         dispense, administer, or order drugs, including
   67         certain controlled substances under certain
   68         circumstances, as of a specified date; amending s.
   69         464.013, F.S.; revising continuing education
   70         requirements for renewal of a license or certificate;
   71         amending s. 464.018, F.S.; specifying acts that
   72         constitute grounds for denial of a license or for
   73         disciplinary action against an advanced registered
   74         nurse practitioner; creating s. 627.42392, F.S.;
   75         defining the term “health insurer”; requiring that
   76         certain health insurers, which do not already use a
   77         certain form, use only a prior authorization form
   78         approved by the Financial Services Commission;
   79         requiring the commission to adopt by rule guidelines
   80         for such forms; amending s. 627.6131, F.S.;
   81         prohibiting a health insurer from retroactively
   82         denying a claim under specified circumstances;
   83         creating s. 627.6466, F.S.; requiring an insurer to
   84         allow a prescribing provider to request an override of
   85         a restriction on the use of medication imposed through
   86         a step-therapy or fail-first protocol; requiring the
   87         insurer to grant such override within a specified
   88         timeframe under certain circumstances; prohibiting the
   89         duration of a step-therapy or fail-first protocol from
   90         exceeding the time period specified by the prescribing
   91         provider; providing that an override is not required
   92         under certain circumstances; amending s. 641.3155,
   93         F.S.; prohibiting a health maintenance organization
   94         from retroactively denying a claim under specified
   95         circumstances; creating s. 641.393, F.S.; requiring a
   96         health maintenance organization to allow a prescribing
   97         provider to request an override of a restriction on
   98         the use of medication imposed through a step-therapy
   99         or fail-first protocol; requiring the health
  100         maintenance organization to grant such override within
  101         a specified timeframe under certain circumstances;
  102         prohibiting the duration of a step-therapy or fail
  103         first protocol from exceeding the time period
  104         specified by the prescribing provider; providing that
  105         an override is not required under certain
  106         circumstances; amending s. 893.02, F.S.; redefining
  107         the term “practitioner” to include advanced registered
  108         nurse practitioners and physician assistants under the
  109         Florida Comprehensive Drug Abuse Prevention and
  110         Control Act for the purpose of prescribing controlled
  111         substances if a certain requirement is met; amending
  112         s. 948.03, F.S.; providing that possession of drugs or
  113         narcotics prescribed by an advanced registered nurse
  114         practitioner or physician assistant does not violate a
  115         prohibition relating to the possession of drugs or
  116         narcotics during probation; amending ss. 458.348 and
  117         459.025, F.S.; conforming provisions to changes made
  118         by the act; reenacting ss. 458.331(10), 458.347(7)(g),
  119         459.015(10), 459.022(7)(f), and 465.0158(5)(b), F.S.,
  120         to incorporate the amendment made to s. 456.072, F.S.,
  121         in references thereto; reenacting ss. 456.072(1)(mm)
  122         and 466.02751, F.S., to incorporate the amendment made
  123         to s. 456.44, F.S., in references thereto; reenacting
  124         ss. 458.303, 458.3475(7)(b), 459.022(4)(e) and (9)(c),
  125         and 459.023(7)(b), F.S., to incorporate the amendment
  126         made to s. 458.347, F.S., in references thereto;
  127         reenacting s. 464.012(3)(c), F.S., to incorporate the
  128         amendment made to s. 464.003, F.S., in a reference
  129         thereto; reenacting ss. 456.041(1)(a), 458.348(1) and
  130         (2), and 459.025(1), F.S., to incorporate the
  131         amendment made to s. 464.012, F.S., in references
  132         thereto; reenacting s. 464.0205(7), F.S., to
  133         incorporate the amendment made to s. 464.013, F.S., in
  134         a reference thereto; reenacting ss. 320.0848(11),
  135         464.008(2), 464.009(5), and 464.0205(1)(b), (3), and
  136         (4)(b), F.S., to incorporate the amendment made to s.
  137         464.018, F.S., in references thereto; reenacting s.
  138         775.051, F.S., to incorporate the amendment made to s.
  139         893.02, F.S., in a reference thereto; reenacting ss.
  140         944.17(3)(a), 948.001(8), and 948.101(1)(e), F.S., to
  141         incorporate the amendment made to s. 948.03, F.S., in
  142         references thereto; providing effective dates.
  143  
  144         WHEREAS, the Legislature recognizes the importance of
  145  access to primary health care for citizens of Florida, most
  146  especially for those who reside in the medically underserved
  147  areas of the state, and
  148         WHEREAS, the Legislature further recognizes that there is a
  149  state and national shortage of primary care providers which
  150  necessitates the removal of regulatory barriers that prevent
  151  advanced registered nurse practitioners and physician assistants
  152  from practicing to the full extent of their education, training,
  153  and certifications, NOW, THEREFORE,
  154  
  155  Be It Enacted by the Legislature of the State of Florida:
  156  
  157         Section 1. Subsection (7) of section 110.12315, Florida
  158  Statutes, is amended to read:
  159         110.12315 Prescription drug program.—The state employees’
  160  prescription drug program is established. This program shall be
  161  administered by the Department of Management Services, according
  162  to the terms and conditions of the plan as established by the
  163  relevant provisions of the annual General Appropriations Act and
  164  implementing legislation, subject to the following conditions:
  165         (7) The department shall establish the reimbursement
  166  schedule for prescription pharmaceuticals dispensed under the
  167  program. Reimbursement rates for a prescription pharmaceutical
  168  must be based on the cost of the generic equivalent drug if a
  169  generic equivalent exists, unless the physician, advanced
  170  registered nurse practitioner, or physician assistant
  171  prescribing the pharmaceutical clearly states on the
  172  prescription that the brand name drug is medically necessary or
  173  that the drug product is included on the formulary of drug
  174  products that may not be interchanged as provided in chapter
  175  465, in which case reimbursement must be based on the cost of
  176  the brand name drug as specified in the reimbursement schedule
  177  adopted by the department.
  178         Section 2. Paragraph (c) of subsection (1) of section
  179  310.071, Florida Statutes, is amended, and subsection (3) of
  180  that section is republished, to read:
  181         310.071 Deputy pilot certification.—
  182         (1) In addition to meeting other requirements specified in
  183  this chapter, each applicant for certification as a deputy pilot
  184  must:
  185         (c) Be in good physical and mental health, as evidenced by
  186  documentary proof of having satisfactorily passed a complete
  187  physical examination administered by a licensed physician within
  188  the preceding 6 months. The board shall adopt rules to establish
  189  requirements for passing the physical examination, which rules
  190  shall establish minimum standards for the physical or mental
  191  capabilities necessary to carry out the professional duties of a
  192  certificated deputy pilot. Such standards shall include zero
  193  tolerance for any controlled substance regulated under chapter
  194  893 unless that individual is under the care of a physician,
  195  advanced registered nurse practitioner, or physician assistant
  196  and that controlled substance was prescribed by that physician,
  197  advanced registered nurse practitioner, or physician assistant.
  198  To maintain eligibility as a certificated deputy pilot, each
  199  certificated deputy pilot must annually provide documentary
  200  proof of having satisfactorily passed a complete physical
  201  examination administered by a licensed physician. The physician
  202  must know the minimum standards and certify that the
  203  certificateholder satisfactorily meets the standards. The
  204  standards for certificateholders shall include a drug test.
  205         (3) The initial certificate issued to a deputy pilot shall
  206  be valid for a period of 12 months, and at the end of this
  207  period, the certificate shall automatically expire and shall not
  208  be renewed. During this period, the board shall thoroughly
  209  evaluate the deputy pilot’s performance for suitability to
  210  continue training and shall make appropriate recommendations to
  211  the department. Upon receipt of a favorable recommendation by
  212  the board, the department shall issue a certificate to the
  213  deputy pilot, which shall be valid for a period of 2 years. The
  214  certificate may be renewed only two times, except in the case of
  215  a fully licensed pilot who is cross-licensed as a deputy pilot
  216  in another port, and provided the deputy pilot meets the
  217  requirements specified for pilots in paragraph (1)(c).
  218         Section 3. Subsection (3) of section 310.073, Florida
  219  Statutes, is amended to read:
  220         310.073 State pilot licensing.—In addition to meeting other
  221  requirements specified in this chapter, each applicant for
  222  license as a state pilot must:
  223         (3) Be in good physical and mental health, as evidenced by
  224  documentary proof of having satisfactorily passed a complete
  225  physical examination administered by a licensed physician within
  226  the preceding 6 months. The board shall adopt rules to establish
  227  requirements for passing the physical examination, which rules
  228  shall establish minimum standards for the physical or mental
  229  capabilities necessary to carry out the professional duties of a
  230  licensed state pilot. Such standards shall include zero
  231  tolerance for any controlled substance regulated under chapter
  232  893 unless that individual is under the care of a physician,
  233  advanced registered nurse practitioner, or physician assistant
  234  and that controlled substance was prescribed by that physician,
  235  advanced registered nurse practitioner, or physician assistant.
  236  To maintain eligibility as a licensed state pilot, each licensed
  237  state pilot must annually provide documentary proof of having
  238  satisfactorily passed a complete physical examination
  239  administered by a licensed physician. The physician must know
  240  the minimum standards and certify that the licensee
  241  satisfactorily meets the standards. The standards for licensees
  242  shall include a drug test.
  243         Section 4. Paragraph (b) of subsection (3) of section
  244  310.081, Florida Statutes, is amended to read:
  245         310.081 Department to examine and license state pilots and
  246  certificate deputy pilots; vacancies.—
  247         (3) Pilots shall hold their licenses or certificates
  248  pursuant to the requirements of this chapter so long as they:
  249         (b) Are in good physical and mental health as evidenced by
  250  documentary proof of having satisfactorily passed a physical
  251  examination administered by a licensed physician or physician
  252  assistant within each calendar year. The board shall adopt rules
  253  to establish requirements for passing the physical examination,
  254  which rules shall establish minimum standards for the physical
  255  or mental capabilities necessary to carry out the professional
  256  duties of a licensed state pilot or a certificated deputy pilot.
  257  Such standards shall include zero tolerance for any controlled
  258  substance regulated under chapter 893 unless that individual is
  259  under the care of a physician, advanced registered nurse
  260  practitioner, or physician assistant and that controlled
  261  substance was prescribed by that physician, advanced registered
  262  nurse practitioner, or physician assistant. To maintain
  263  eligibility as a certificated deputy pilot or licensed state
  264  pilot, each certificated deputy pilot or licensed state pilot
  265  must annually provide documentary proof of having satisfactorily
  266  passed a complete physical examination administered by a
  267  licensed physician. The physician must know the minimum
  268  standards and certify that the certificateholder or licensee
  269  satisfactorily meets the standards. The standards for
  270  certificateholders and for licensees shall include a drug test.
  271  
  272  Upon resignation or in the case of disability permanently
  273  affecting a pilot’s ability to serve, the state license or
  274  certificate issued under this chapter shall be revoked by the
  275  department.
  276         Section 5. Section 383.336, Florida Statutes, is repealed.
  277         Section 6. Section 395.1051, Florida Statutes, is amended
  278  to read:
  279         395.1051 Duty to notify patients and physicians.—
  280         (1) An appropriately trained person designated by each
  281  licensed facility shall inform each patient, or an individual
  282  identified pursuant to s. 765.401(1), in person about adverse
  283  incidents that result in serious harm to the patient.
  284  Notification of outcomes of care that result in harm to the
  285  patient under this section does shall not constitute an
  286  acknowledgment or admission of liability and may not, nor can it
  287  be introduced as evidence.
  288         (2) A hospital shall notify each obstetrical physician who
  289  has privileges at the hospital at least 90 days before the
  290  hospital closes its obstetrical department or ceases to provide
  291  obstetrical services.
  292         Section 7. Paragraph (c) of subsection (2) of section
  293  409.967, Florida Statutes, is amended to read:
  294         409.967 Managed care plan accountability.—
  295         (2) The agency shall establish such contract requirements
  296  as are necessary for the operation of the statewide managed care
  297  program. In addition to any other provisions the agency may deem
  298  necessary, the contract must require:
  299         (c) Access.—
  300         1. The agency shall establish specific standards for the
  301  number, type, and regional distribution of providers in managed
  302  care plan networks to ensure access to care for both adults and
  303  children. Each plan must maintain a regionwide network of
  304  providers in sufficient numbers to meet the access standards for
  305  specific medical services for all recipients enrolled in the
  306  plan. The exclusive use of mail-order pharmacies may not be
  307  sufficient to meet network access standards. Consistent with the
  308  standards established by the agency, provider networks may
  309  include providers located outside the region. A plan may
  310  contract with a new hospital facility before the date the
  311  hospital becomes operational if the hospital has commenced
  312  construction, will be licensed and operational by January 1,
  313  2013, and a final order has issued in any civil or
  314  administrative challenge. Each plan shall establish and maintain
  315  an accurate and complete electronic database of contracted
  316  providers, including information about licensure or
  317  registration, locations and hours of operation, specialty
  318  credentials and other certifications, specific performance
  319  indicators, and such other information as the agency deems
  320  necessary. The database must be available online to both the
  321  agency and the public and have the capability to compare the
  322  availability of providers to network adequacy standards and to
  323  accept and display feedback from each provider’s patients. Each
  324  plan shall submit quarterly reports to the agency identifying
  325  the number of enrollees assigned to each primary care provider.
  326         2. Each managed care plan must publish any prescribed drug
  327  formulary or preferred drug list on the plan’s website in a
  328  manner that is accessible to and searchable by enrollees and
  329  providers. The plan must update the list within 24 hours after
  330  making a change. Each plan must ensure that the prior
  331  authorization process for prescribed drugs is readily accessible
  332  to health care providers, including posting appropriate contact
  333  information on its website and providing timely responses to
  334  providers. For Medicaid recipients diagnosed with hemophilia who
  335  have been prescribed anti-hemophilic-factor replacement
  336  products, the agency shall provide for those products and
  337  hemophilia overlay services through the agency’s hemophilia
  338  disease management program.
  339         3. Managed care plans, and their fiscal agents or
  340  intermediaries, must accept prior authorization requests for any
  341  service electronically.
  342         4. Managed care plans serving children in the care and
  343  custody of the Department of Children and Families must maintain
  344  complete medical, dental, and behavioral health encounter
  345  information and participate in making such information available
  346  to the department or the applicable contracted community-based
  347  care lead agency for use in providing comprehensive and
  348  coordinated case management. The agency and the department shall
  349  establish an interagency agreement to provide guidance for the
  350  format, confidentiality, recipient, scope, and method of
  351  information to be made available and the deadlines for
  352  submission of the data. The scope of information available to
  353  the department shall be the data that managed care plans are
  354  required to submit to the agency. The agency shall determine the
  355  plan’s compliance with standards for access to medical, dental,
  356  and behavioral health services; the use of medications; and
  357  followup on all medically necessary services recommended as a
  358  result of early and periodic screening, diagnosis, and
  359  treatment.
  360         5. If medication for the treatment of a medical condition
  361  is restricted for use by a managed care plan through a step
  362  therapy or fail-first protocol, the prescribing provider shall
  363  have access to a clear and convenient process to request an
  364  override of such restriction from the managed care plan. The
  365  managed care plan shall grant an override of the protocol within
  366  24 hours if:
  367         a. The prescribing provider determines, based on sound
  368  clinical evidence, that the preferred treatment required under
  369  the step-therapy or fail-first protocol has been ineffective in
  370  the treatment of the enrollee’s disease or medical condition; or
  371         b. The prescribing provider believes, based on sound
  372  clinical evidence or medical and scientific evidence, that the
  373  preferred treatment required under the step-therapy or fail
  374  first protocol:
  375         (I) Is expected to, or is likely to, be ineffective given
  376  the known relevant physical or mental characteristics and
  377  medical history of the enrollee and the known characteristics of
  378  the drug regimen; or
  379         (II) Will cause, or is likely to cause, an adverse reaction
  380  or other physical harm to the enrollee.
  381         6. If the prescribing provider allows the enrollee to enter
  382  the step-therapy or fail-first protocol recommended by the
  383  managed care plan, the duration of the step-therapy or fail
  384  first protocol may not exceed a period deemed appropriate by the
  385  prescribing provider. If the prescribing provider deems the
  386  treatment clinically ineffective, the enrollee is entitled to
  387  receive the recommended course of therapy without requiring the
  388  prescribing provider to seek approval for an override of the
  389  step-therapy or fail-first protocol.
  390         Section 8. Subsection (7) of section 456.072, Florida
  391  Statutes, is amended to read:
  392         456.072 Grounds for discipline; penalties; enforcement.—
  393         (7) Notwithstanding subsection (2), upon a finding that a
  394  physician has prescribed or dispensed a controlled substance, or
  395  caused a controlled substance to be prescribed or dispensed, in
  396  a manner that violates the standard of practice set forth in s.
  397  458.331(1)(q) or (t), s. 459.015(1)(t) or (x), s. 461.013(1)(o)
  398  or (s), or s. 466.028(1)(p) or (x), or that an advanced
  399  registered nurse practitioner has prescribed or dispensed a
  400  controlled substance, or caused a controlled substance to be
  401  prescribed or dispensed in a manner that violates the standard
  402  of practice set forth in s. 464.018(1)(n) or s. 464.018(1)(p)6.,
  403  the physician or advanced registered nurse practitioner shall be
  404  suspended for a period of not less than 6 months and pay a fine
  405  of not less than $10,000 per count. Repeated violations shall
  406  result in increased penalties.
  407         Section 9. Subsections (2) and (3) of section 456.44,
  408  Florida Statutes, are amended to read:
  409         456.44 Controlled substance prescribing.—
  410         (2) REGISTRATION.—Effective January 1, 2012, A physician
  411  licensed under chapter 458, chapter 459, chapter 461, or chapter
  412  466, a physician assistant licensed under chapter 458 or chapter
  413  459, or an advanced registered nurse practitioner certified
  414  under part I of chapter 464 who prescribes any controlled
  415  substance, listed in Schedule II, Schedule III, or Schedule IV
  416  as defined in s. 893.03, for the treatment of chronic
  417  nonmalignant pain, must:
  418         (a) Designate himself or herself as a controlled substance
  419  prescribing practitioner on his or her the physician’s
  420  practitioner profile.
  421         (b) Comply with the requirements of this section and
  422  applicable board rules.
  423         (3) STANDARDS OF PRACTICE.—The standards of practice in
  424  this section do not supersede the level of care, skill, and
  425  treatment recognized in general law related to health care
  426  licensure.
  427         (a) A complete medical history and a physical examination
  428  must be conducted before beginning any treatment and must be
  429  documented in the medical record. The exact components of the
  430  physical examination shall be left to the judgment of the
  431  registrant clinician who is expected to perform a physical
  432  examination proportionate to the diagnosis that justifies a
  433  treatment. The medical record must, at a minimum, document the
  434  nature and intensity of the pain, current and past treatments
  435  for pain, underlying or coexisting diseases or conditions, the
  436  effect of the pain on physical and psychological function, a
  437  review of previous medical records, previous diagnostic studies,
  438  and history of alcohol and substance abuse. The medical record
  439  shall also document the presence of one or more recognized
  440  medical indications for the use of a controlled substance. Each
  441  registrant must develop a written plan for assessing each
  442  patient’s risk of aberrant drug-related behavior, which may
  443  include patient drug testing. Registrants must assess each
  444  patient’s risk for aberrant drug-related behavior and monitor
  445  that risk on an ongoing basis in accordance with the plan.
  446         (b) Each registrant must develop a written individualized
  447  treatment plan for each patient. The treatment plan shall state
  448  objectives that will be used to determine treatment success,
  449  such as pain relief and improved physical and psychosocial
  450  function, and shall indicate if any further diagnostic
  451  evaluations or other treatments are planned. After treatment
  452  begins, the registrant physician shall adjust drug therapy to
  453  the individual medical needs of each patient. Other treatment
  454  modalities, including a rehabilitation program, shall be
  455  considered depending on the etiology of the pain and the extent
  456  to which the pain is associated with physical and psychosocial
  457  impairment. The interdisciplinary nature of the treatment plan
  458  shall be documented.
  459         (c) The registrant physician shall discuss the risks and
  460  benefits of the use of controlled substances, including the
  461  risks of abuse and addiction, as well as physical dependence and
  462  its consequences, with the patient, persons designated by the
  463  patient, or the patient’s surrogate or guardian if the patient
  464  is incompetent. The registrant physician shall use a written
  465  controlled substance agreement between the registrant physician
  466  and the patient outlining the patient’s responsibilities,
  467  including, but not limited to:
  468         1. Number and frequency of controlled substance
  469  prescriptions and refills.
  470         2. Patient compliance and reasons for which drug therapy
  471  may be discontinued, such as a violation of the agreement.
  472         3. An agreement that controlled substances for the
  473  treatment of chronic nonmalignant pain shall be prescribed by a
  474  single treating registrant physician unless otherwise authorized
  475  by the treating registrant physician and documented in the
  476  medical record.
  477         (d) The patient shall be seen by the registrant physician
  478  at regular intervals, not to exceed 3 months, to assess the
  479  efficacy of treatment, ensure that controlled substance therapy
  480  remains indicated, evaluate the patient’s progress toward
  481  treatment objectives, consider adverse drug effects, and review
  482  the etiology of the pain. Continuation or modification of
  483  therapy shall depend on the registrant’s physician’s evaluation
  484  of the patient’s progress. If treatment goals are not being
  485  achieved, despite medication adjustments, the registrant
  486  physician shall reevaluate the appropriateness of continued
  487  treatment. The registrant physician shall monitor patient
  488  compliance in medication usage, related treatment plans,
  489  controlled substance agreements, and indications of substance
  490  abuse or diversion at a minimum of 3-month intervals.
  491         (e) The registrant physician shall refer the patient as
  492  necessary for additional evaluation and treatment in order to
  493  achieve treatment objectives. Special attention shall be given
  494  to those patients who are at risk for misusing their medications
  495  and those whose living arrangements pose a risk for medication
  496  misuse or diversion. The management of pain in patients with a
  497  history of substance abuse or with a comorbid psychiatric
  498  disorder requires extra care, monitoring, and documentation and
  499  requires consultation with or referral to an addiction medicine
  500  specialist or psychiatrist.
  501         (f) A registrant physician registered under this section
  502  must maintain accurate, current, and complete records that are
  503  accessible and readily available for review and comply with the
  504  requirements of this section, the applicable practice act, and
  505  applicable board rules. The medical records must include, but
  506  are not limited to:
  507         1. The complete medical history and a physical examination,
  508  including history of drug abuse or dependence.
  509         2. Diagnostic, therapeutic, and laboratory results.
  510         3. Evaluations and consultations.
  511         4. Treatment objectives.
  512         5. Discussion of risks and benefits.
  513         6. Treatments.
  514         7. Medications, including date, type, dosage, and quantity
  515  prescribed.
  516         8. Instructions and agreements.
  517         9. Periodic reviews.
  518         10. Results of any drug testing.
  519         11. A photocopy of the patient’s government-issued photo
  520  identification.
  521         12. If a written prescription for a controlled substance is
  522  given to the patient, a duplicate of the prescription.
  523         13. The registrant’s physician’s full name presented in a
  524  legible manner.
  525         (g) Patients with signs or symptoms of substance abuse
  526  shall be immediately referred to a board-certified pain
  527  management physician, an addiction medicine specialist, or a
  528  mental health addiction facility as it pertains to drug abuse or
  529  addiction unless the registrant is a physician who is board
  530  certified or board-eligible in pain management. Throughout the
  531  period of time before receiving the consultant’s report, a
  532  prescribing registrant physician shall clearly and completely
  533  document medical justification for continued treatment with
  534  controlled substances and those steps taken to ensure medically
  535  appropriate use of controlled substances by the patient. Upon
  536  receipt of the consultant’s written report, the prescribing
  537  registrant physician shall incorporate the consultant’s
  538  recommendations for continuing, modifying, or discontinuing
  539  controlled substance therapy. The resulting changes in treatment
  540  shall be specifically documented in the patient’s medical
  541  record. Evidence or behavioral indications of diversion shall be
  542  followed by discontinuation of controlled substance therapy, and
  543  the patient shall be discharged, and all results of testing and
  544  actions taken by the registrant physician shall be documented in
  545  the patient’s medical record.
  546  
  547  This subsection does not apply to a board-eligible or board
  548  certified anesthesiologist, physiatrist, rheumatologist, or
  549  neurologist, or to a board-certified physician who has surgical
  550  privileges at a hospital or ambulatory surgery center and
  551  primarily provides surgical services. This subsection does not
  552  apply to a board-eligible or board-certified medical specialist
  553  who has also completed a fellowship in pain medicine approved by
  554  the Accreditation Council for Graduate Medical Education or the
  555  American Osteopathic Association, or who is board eligible or
  556  board certified in pain medicine by the American Board of Pain
  557  Medicine, the American Board of Interventional Pain Physicians,
  558  the American Association of Physician Specialists, or a board
  559  approved by the American Board of Medical Specialties or the
  560  American Osteopathic Association and performs interventional
  561  pain procedures of the type routinely billed using surgical
  562  codes. This subsection does not apply to a registrant, advanced
  563  registered nurse practitioner, or physician assistant who
  564  prescribes medically necessary controlled substances for a
  565  patient during an inpatient stay in a hospital licensed under
  566  chapter 395.
  567         Section 10. Section 458.326, Florida Statutes, is amended
  568  to read:
  569         458.326 Intractable pain; authorized treatment;
  570  interventional pain medicine; unauthorized practice.—
  571         (1)(a) For the purposes of this subsection section, the
  572  term “intractable pain” means pain for which, in the generally
  573  accepted course of medical practice, the cause cannot be removed
  574  and otherwise treated.
  575         (b)(2) Intractable pain must be diagnosed by a physician
  576  licensed under this chapter and qualified by experience to
  577  render such diagnosis.
  578         (c)(3) Notwithstanding any other provision of law, a
  579  physician may prescribe or administer any controlled substance
  580  under Schedules II-V, as provided for in s. 893.03, to a person
  581  for the treatment of intractable pain, provided the physician
  582  does so in accordance with that level of care, skill, and
  583  treatment recognized by a reasonably prudent physician under
  584  similar conditions and circumstances.
  585         (d)(4) Nothing in this section shall be construed to
  586  condone, authorize, or approve mercy killing or euthanasia, and
  587  no treatment authorized by this section may be used for such
  588  purpose.
  589         (2)(a) For the purposes of this subsection, the term
  590  “interventional pain medicine” means the practice of medicine
  591  devoted to the diagnosis and treatment of pain-related
  592  disorders, principally with the application of interventional
  593  techniques in managing chronic, intractable pain, independently
  594  or in conjunction with other treatment modalities. These
  595  techniques include minimally invasive procedures, including
  596  percutaneous precision needle placement, with placement of drugs
  597  in targeted areas or destruction of targeted nerves, and some
  598  surgical techniques such as laser or endoscopic discectomy,
  599  cement stabilization of spine fractures, intrathecal infusion
  600  pumps, and spinal cord stimulators, for the diagnosis and
  601  management of chronic, intractable pain.
  602         (b) A person may not practice interventional pain medicine
  603  or offer to practice interventional pain medicine unless such
  604  acts are performed at facilities licensed under chapter 395 or
  605  are performed by or under the direct supervision of a physician
  606  licensed under this chapter or an osteopathic physician licensed
  607  under chapter 459.
  608         Section 11. Paragraph (b) of subsection (2) of section
  609  458.3265, Florida Statutes, is amended to read:
  610         458.3265 Pain-management clinics.—
  611         (2) PHYSICIAN RESPONSIBILITIES.—These responsibilities
  612  apply to any physician who provides professional services in a
  613  pain-management clinic that is required to be registered in
  614  subsection (1).
  615         (b) A person may not dispense any medication on the
  616  premises of a registered pain-management clinic unless he or she
  617  is a physician licensed under this chapter or chapter 459. A
  618  person may not prescribe any controlled substance regulated
  619  under chapter 893 on the premises of a registered pain
  620  management clinic unless he or she is a physician licensed under
  621  this chapter or chapter 459.
  622         Section 12. Paragraph (b) of subsection (2) of section
  623  459.0137, Florida Statutes, is amended to read:
  624         459.0137 Pain-management clinics.—
  625         (2) PHYSICIAN RESPONSIBILITIES.—These responsibilities
  626  apply to any osteopathic physician who provides professional
  627  services in a pain-management clinic that is required to be
  628  registered in subsection (1).
  629         (b) A person may not dispense any medication on the
  630  premises of a registered pain-management clinic unless he or she
  631  is a physician licensed under this chapter or chapter 458. A
  632  person may not prescribe any controlled substance regulated
  633  under chapter 893 on the premises of a registered pain
  634  management clinic unless he or she is a physician licensed under
  635  this chapter or chapter 458.
  636         Section 13. Paragraph (e) of subsection (4) of section
  637  458.347, Florida Statutes, is amended, and paragraph (c) of
  638  subsection (9) of that section is republished, to read:
  639         458.347 Physician assistants.—
  640         (4) PERFORMANCE OF PHYSICIAN ASSISTANTS.—
  641         (e) A supervisory physician may delegate to a fully
  642  licensed physician assistant the authority to prescribe or
  643  dispense any medication used in the supervisory physician’s
  644  practice unless such medication is listed on the formulary
  645  created pursuant to paragraph (f). A fully licensed physician
  646  assistant may only prescribe or dispense such medication under
  647  the following circumstances:
  648         1. A physician assistant must clearly identify to the
  649  patient that he or she is a physician assistant. Furthermore,
  650  the physician assistant must inform the patient that the patient
  651  has the right to see the physician prior to any prescription
  652  being prescribed or dispensed by the physician assistant.
  653         2. The supervisory physician must notify the department of
  654  his or her intent to delegate, on a department-approved form,
  655  before delegating such authority and notify the department of
  656  any change in prescriptive privileges of the physician
  657  assistant. Authority to dispense may be delegated only by a
  658  supervising physician who is registered as a dispensing
  659  practitioner in compliance with s. 465.0276.
  660         3. The physician assistant must file with the department a
  661  signed affidavit that he or she has completed a minimum of 10
  662  continuing medical education hours in the specialty practice in
  663  which the physician assistant has prescriptive privileges with
  664  each licensure renewal application. Three of the 10 hours must
  665  consist of a continuing education course on the safe and
  666  effective prescribing of controlled substance medications, which
  667  shall be offered by a statewide professional association of
  668  physicians in this state accredited to provide educational
  669  activities designated for the American Medical Association
  670  Physician’s Recognition Award Category I Credit.
  671         4. The department may issue a prescriber number to the
  672  physician assistant granting authority for the prescribing of
  673  medicinal drugs authorized within this paragraph upon completion
  674  of the foregoing requirements. The physician assistant shall not
  675  be required to independently register pursuant to s. 465.0276.
  676         5. The prescription must be written in a form that complies
  677  with chapter 499 and must contain, in addition to the
  678  supervisory physician’s name, address, and telephone number, the
  679  physician assistant’s prescriber number. Unless it is a drug or
  680  drug sample dispensed by the physician assistant, the
  681  prescription must be filled in a pharmacy permitted under
  682  chapter 465 and must be dispensed in that pharmacy by a
  683  pharmacist licensed under chapter 465. The appearance of the
  684  prescriber number creates a presumption that the physician
  685  assistant is authorized to prescribe the medicinal drug and the
  686  prescription is valid.
  687         6. The physician assistant must note the prescription or
  688  dispensing of medication in the appropriate medical record.
  689         (9) COUNCIL ON PHYSICIAN ASSISTANTS.—The Council on
  690  Physician Assistants is created within the department.
  691         (c) The council shall:
  692         1. Recommend to the department the licensure of physician
  693  assistants.
  694         2. Develop all rules regulating the use of physician
  695  assistants by physicians under this chapter and chapter 459,
  696  except for rules relating to the formulary developed under
  697  paragraph (4)(f). The council shall also develop rules to ensure
  698  that the continuity of supervision is maintained in each
  699  practice setting. The boards shall consider adopting a proposed
  700  rule developed by the council at the regularly scheduled meeting
  701  immediately following the submission of the proposed rule by the
  702  council. A proposed rule submitted by the council may not be
  703  adopted by either board unless both boards have accepted and
  704  approved the identical language contained in the proposed rule.
  705  The language of all proposed rules submitted by the council must
  706  be approved by both boards pursuant to each respective board’s
  707  guidelines and standards regarding the adoption of proposed
  708  rules. If either board rejects the council’s proposed rule, that
  709  board must specify its objection to the council with
  710  particularity and include any recommendations it may have for
  711  the modification of the proposed rule.
  712         3. Make recommendations to the boards regarding all matters
  713  relating to physician assistants.
  714         4. Address concerns and problems of practicing physician
  715  assistants in order to improve safety in the clinical practices
  716  of licensed physician assistants.
  717         Section 14. Effective January 1, 2016, paragraph (f) of
  718  subsection (4) of section 458.347, Florida Statutes, is amended
  719  to read:
  720         458.347 Physician assistants.—
  721         (4) PERFORMANCE OF PHYSICIAN ASSISTANTS.—
  722         (f)1. The council shall establish a formulary of medicinal
  723  drugs that a fully licensed physician assistant having
  724  prescribing authority under this section or s. 459.022 may not
  725  prescribe. The formulary must include controlled substances as
  726  defined in chapter 893, general anesthetics, and radiographic
  727  contrast materials, and must limit the prescription of Schedule
  728  II controlled substances as defined in s. 893.03 to a 7-day
  729  supply. The formulary must also restrict the prescribing of
  730  psychiatric mental health controlled substances for children
  731  under 18 years of age.
  732         2. In establishing the formulary, the council shall consult
  733  with a pharmacist licensed under chapter 465, but not licensed
  734  under this chapter or chapter 459, who shall be selected by the
  735  State Surgeon General.
  736         3. Only the council shall add to, delete from, or modify
  737  the formulary. Any person who requests an addition, deletion, or
  738  modification of a medicinal drug listed on such formulary has
  739  the burden of proof to show cause why such addition, deletion,
  740  or modification should be made.
  741         4. The boards shall adopt the formulary required by this
  742  paragraph, and each addition, deletion, or modification to the
  743  formulary, by rule. Notwithstanding any provision of chapter 120
  744  to the contrary, the formulary rule shall be effective 60 days
  745  after the date it is filed with the Secretary of State. Upon
  746  adoption of the formulary, the department shall mail a copy of
  747  such formulary to each fully licensed physician assistant having
  748  prescribing authority under this section or s. 459.022, and to
  749  each pharmacy licensed by the state. The boards shall establish,
  750  by rule, a fee not to exceed $200 to fund the provisions of this
  751  paragraph and paragraph (e).
  752         Section 15. Subsection (2) of section 464.003, Florida
  753  Statutes, is amended to read:
  754         464.003 Definitions.—As used in this part, the term:
  755         (2) “Advanced or specialized nursing practice” means, in
  756  addition to the practice of professional nursing, the
  757  performance of advanced-level nursing acts approved by the board
  758  which, by virtue of postbasic specialized education, training,
  759  and experience, are appropriately performed by an advanced
  760  registered nurse practitioner. Within the context of advanced or
  761  specialized nursing practice, the advanced registered nurse
  762  practitioner may perform acts of nursing diagnosis and nursing
  763  treatment of alterations of the health status. The advanced
  764  registered nurse practitioner may also perform acts of medical
  765  diagnosis and treatment, prescription, and operation as
  766  authorized within the framework of an established supervisory
  767  protocol which are identified and approved by a joint committee
  768  composed of three members appointed by the Board of Nursing, two
  769  of whom must be advanced registered nurse practitioners; three
  770  members appointed by the Board of Medicine, two of whom must
  771  have had work experience with advanced registered nurse
  772  practitioners; and the State Surgeon General or the State
  773  Surgeon General’s designee. Each committee member appointed by a
  774  board shall be appointed to a term of 4 years unless a shorter
  775  term is required to establish or maintain staggered terms. The
  776  Board of Nursing shall adopt rules authorizing the performance
  777  of any such acts approved by the joint committee. Unless
  778  otherwise specified by the joint committee, such acts must be
  779  performed under the general supervision of a practitioner
  780  licensed under chapter 458, chapter 459, or chapter 466 within
  781  the framework of standing protocols which identify the medical
  782  acts to be performed and the conditions for their performance.
  783  The department may, by rule, require that a copy of the protocol
  784  be filed with the department along with the notice required by
  785  s. 458.348.
  786         Section 16. Subsection (6) is added to section 464.012,
  787  Florida Statutes, to read:
  788         464.012 Certification of advanced registered nurse
  789  practitioners; fees; controlled substance prescribing.—
  790         (6)(a) The board shall establish a committee to recommend a
  791  formulary of controlled substances that an advanced registered
  792  nurse practitioner may not prescribe or may prescribe only for
  793  specific uses or in limited quantities. The committee must
  794  consist of three advanced registered nurse practitioners
  795  licensed under s. 464.012, recommended by the Board of Nursing;
  796  three physicians licensed under chapter 458 or chapter 459 who
  797  have had work experience with advanced registered nurse
  798  practitioners, recommended by the Board of Medicine; and a
  799  pharmacist licensed under chapter 465 who holds a Doctor of
  800  Pharmacy degree, recommended by the Board of Pharmacy. The
  801  committee may recommend an evidence-based formulary applicable
  802  to all advanced registered nurse practitioners, which is limited
  803  by specially certification or to approved uses of controlled
  804  substances, or subject to other similar restrictions the
  805  committee finds are necessary to protect the health, safety, and
  806  welfare of the public. The formulary must restrict the
  807  prescribing of psychiatric mental health controlled substances
  808  for children under 18 years of age to psychiatric nurses as
  809  defined in s. 394.455. The formulary must also limit the
  810  prescribing of Schedule II controlled substances as defined in
  811  s. 893.03 to a 7-day supply, except that such restriction does
  812  not apply to controlled substances that are psychiatric
  813  medications prescribed by psychiatric nurses as defined in s.
  814  394.455.
  815         (b)The board shall adopt by rule the recommended formulary
  816  and recommended additions or deletions to the formulary which it
  817  finds are supported by evidence-based clinical findings
  818  presented by the Board of Medicine, the Board of Osteopathic
  819  Medicine, or the Board of Dentistry.
  820         (c)The formulary required under this subsection does not
  821  apply to a controlled substance order that is dispensed for
  822  administration including orders for medication authorized in
  823  subparagraph (4)(a)3. or subparagraph (4)(a)4.
  824         (d) The board shall adopt the committee’s initial
  825  recommendation no later January 1, 2016.
  826         Section 17. Effective January 1, 2016, subsection (3) of
  827  section 464.012, Florida Statutes, is amended to read:
  828         464.012 Certification of advanced registered nurse
  829  practitioners; fees; controlled substance prescribing.—
  830         (3) An advanced registered nurse practitioner shall perform
  831  those functions authorized in this section within the framework
  832  of an established protocol that is filed with the board upon
  833  biennial license renewal and within 30 days after entering into
  834  a supervisory relationship with a physician or changes to the
  835  protocol. The board shall review the protocol to ensure
  836  compliance with applicable regulatory standards for protocols.
  837  The board shall refer to the department licensees submitting
  838  protocols that are not compliant with the regulatory standards
  839  for protocols. A practitioner currently licensed under chapter
  840  458, chapter 459, or chapter 466 shall maintain supervision for
  841  directing the specific course of medical treatment. Within the
  842  established framework, an advanced registered nurse practitioner
  843  may:
  844         (a) Prescribe, dispense, administer, or order any drug;
  845  however, an advanced registered nurse practitioner may only
  846  prescribe or dispense a controlled substance as defined in s.
  847  893.03 if the advanced registered nurse practitioner has
  848  graduated from a program leading to a master’s degree in a
  849  clinical nursing specialty area with training in specialized
  850  practitioner skills. Monitor and alter drug therapies.
  851         (b) Initiate appropriate therapies for certain conditions.
  852         (c) Perform additional functions as may be determined by
  853  rule in accordance with s. 464.003(2).
  854         (d) Order diagnostic tests and physical and occupational
  855  therapy.
  856         Section 18. Subsection (3) of section 464.013, Florida
  857  Statutes, is amended to read:
  858         464.013 Renewal of license or certificate.—
  859         (3) The board shall by rule prescribe up to 30 hours of
  860  continuing education biennially as a condition for renewal of a
  861  license or certificate.
  862         (a) A nurse who is certified by a health care specialty
  863  program accredited by the National Commission for Certifying
  864  Agencies or the Accreditation Board for Specialty Nursing
  865  Certification is exempt from continuing education requirements.
  866  The criteria for programs must shall be approved by the board.
  867         (b) Notwithstanding the exemption in paragraph (a), as part
  868  of the maximum 30 hours of continuing education hours required
  869  under this subsection, advanced registered nurse practitioners
  870  certified under s. 464.012 must complete at least 3 hours of
  871  continuing education on the safe and effective prescription of
  872  controlled substances. Such continuing education courses must be
  873  offered by a statewide professional association of physicians in
  874  this state accredited to provide educational activities
  875  designated for the American Medical Association Physician’s
  876  Recognition Award Category 1 Credit, the American Nurses
  877  Credentialing Center, or the American Association of Nurse
  878  Practitioners and may be offered in a distance-learning format.
  879         Section 19. Paragraph (p) is added to subsection (1) of
  880  section 464.018, Florida Statutes, and subsection (2) of that
  881  section is republished, to read:
  882         464.018 Disciplinary actions.—
  883         (1) The following acts constitute grounds for denial of a
  884  license or disciplinary action, as specified in s. 456.072(2):
  885         (p)For an advanced registered nurse practitioner:
  886         1.Presigning blank prescription forms.
  887         2.Prescribing for office use any medicinal drug appearing
  888  on Schedule II in chapter 893.
  889         3.Prescribing, ordering, dispensing, administering,
  890  supplying, selling, or giving a drug that is an amphetamine or a
  891  sympathomimetic amine drug, or a compound designated pursuant to
  892  chapter 893 as a Schedule II controlled substance, to or for any
  893  person except for:
  894         a. The treatment of narcolepsy; hyperkinesis; behavioral
  895  syndrome in children characterized by the developmentally
  896  inappropriate symptoms of moderate to severe distractibility,
  897  short attention span, hyperactivity, emotional lability, and
  898  impulsivity; or drug-induced brain dysfunction.
  899         b. The differential diagnostic psychiatric evaluation of
  900  depression or the treatment of depression shown to be refractory
  901  to other therapeutic modalities.
  902         c. The clinical investigation of the effects of such drugs
  903  or compounds when an investigative protocol is submitted to,
  904  reviewed by, and approved by the department before such
  905  investigation is begun.
  906         4. Prescribing, ordering, dispensing, administering,
  907  supplying, selling, or giving growth hormones, testosterone or
  908  its analogs, human chorionic gonadotropin (HCG), or other
  909  hormones for the purpose of muscle building or to enhance
  910  athletic performance. As used in this subparagraph, the term
  911  “muscle building” does not include the treatment of injured
  912  muscle. A prescription written for the drug products listed in
  913  this paragraph may be dispensed by a pharmacist with the
  914  presumption that the prescription is for legitimate medical use.
  915         5. Promoting or advertising on any prescription form a
  916  community pharmacy unless the form also states: “This
  917  prescription may be filled at any pharmacy of your choice.”
  918         6.Prescribing, dispensing, administering, mixing, or
  919  otherwise preparing a legend drug, including a controlled
  920  substance, other than in the course of his or her professional
  921  practice. For the purposes of this subparagraph, it is legally
  922  presumed that prescribing, dispensing, administering, mixing, or
  923  otherwise preparing legend drugs, including all controlled
  924  substances, inappropriately or in excessive or inappropriate
  925  quantities is not in the best interest of the patient and is not
  926  in the course of the advanced registered nurse practitioner’s
  927  professional practice, without regard to his or her intent.
  928         7.Prescribing, dispensing, or administering a medicinal
  929  drug appearing on any schedule set forth in chapter 893 to
  930  himself or herself, except a drug prescribed, dispensed, or
  931  administered to the advanced registered nurse practitioner by
  932  another practitioner authorized to prescribe, dispense, or
  933  administer medicinal drugs.
  934         8.Prescribing, ordering, dispensing, administering,
  935  supplying, selling, or giving amygdalin (laetrile) to any
  936  person.
  937         9.Dispensing a controlled substance listed on Schedule II
  938  or Schedule III in chapter 893 in violation of s. 465.0276.
  939         10.Promoting or advertising through any communication
  940  medium the use, sale, or dispensing of a controlled substance
  941  appearing on any schedule in chapter 893.
  942         (2) The board may enter an order denying licensure or
  943  imposing any of the penalties in s. 456.072(2) against any
  944  applicant for licensure or licensee who is found guilty of
  945  violating any provision of subsection (1) of this section or who
  946  is found guilty of violating any provision of s. 456.072(1).
  947         Section 20. Section 627.42392, Florida Statutes, is created
  948  to read:
  949         627.42392 Prior authorization.—
  950         (1)As used in this section, the term “health insurer”
  951  means an authorized insurer offering health insurance as defined
  952  in s. 624.603, a managed care plan as defined in s. 409.901(13),
  953  or a health maintenance organization as defined in s.
  954  641.19(12).
  955         (2) Notwithstanding any other provision of law, in order to
  956  establish uniformity in the submission of prior authorization
  957  forms on or after January 1, 2016, a health insurer, or a
  958  pharmacy benefits manager on behalf of the health insurer, which
  959  does not use an online prior authorization form for its
  960  contracted providers shall use only the prior authorization form
  961  that has been approved by the Financial Services Commission to
  962  obtain a prior authorization for a medical procedure, course of
  963  treatment, or prescription drug benefit. Such form may not
  964  exceed two pages in length, excluding any instructions or
  965  guiding documentation.
  966         (3) The Financial Services Commission shall adopt by rule
  967  guidelines for prior authorization forms which ensure the
  968  general uniformity of such forms.
  969         Section 21. Subsection (11) of section 627.6131, Florida
  970  Statutes, is amended to read:
  971         627.6131 Payment of claims.—
  972         (11) A health insurer may not retroactively deny a claim
  973  because of insured ineligibility:
  974         (a)At any time, if the health insurer verified the
  975  eligibility of an insured at the time of treatment and provided
  976  an authorization number.
  977         (b) More than 1 year after the date of payment of the
  978  claim.
  979         Section 22. Section 627.6466, Florida Statutes, is created
  980  to read:
  981         627.6466 Fail-first protocols.—If medication for the
  982  treatment of a medical condition is restricted for use by an
  983  insurer through a step-therapy or fail-first protocol, the
  984  prescribing provider shall have access to a clear and convenient
  985  process to request an override of such restriction from the
  986  insurer. The insurer shall grant an override of the protocol
  987  within 24 hours under the following circumstances:
  988         (1) The prescribing provider determines, based on sound
  989  clinical evidence, that the preferred treatment required under
  990  the step-therapy or fail-first protocol has been ineffective in
  991  the treatment of the insured’s disease or medical condition; or
  992         (2)The prescribing provider believes, based on sound
  993  clinical evidence or medical and scientific evidence, that the
  994  preferred treatment required under the step-therapy or fail
  995  first protocol:
  996         (a) Is expected to, or is likely to, be ineffective given
  997  the known relevant physical or mental characteristics and
  998  medical history of the insured and the known characteristics of
  999  the drug regimen; or
 1000         (b) Will cause, or is likely to cause, an adverse reaction
 1001  or other physical harm to the insured.
 1002         (3) If the prescribing provider allows the insured to enter
 1003  the step-therapy or fail-first protocol recommended by the
 1004  health insurer, the duration of the step-therapy or fail-first
 1005  protocol may not exceed a period deemed appropriate by the
 1006  provider. If the prescribing provider deems the treatment
 1007  clinically ineffective, the insured is entitled to receive the
 1008  recommended course of therapy without requiring the prescribing
 1009  provider to seek approval for an override of the step-therapy or
 1010  fail-first protocol.
 1011         Section 23. Subsection (10) of section 641.3155, Florida
 1012  Statutes, is amended to read:
 1013         641.3155 Prompt payment of claims.—
 1014         (10) A health maintenance organization may not
 1015  retroactively deny a claim because of subscriber ineligibility:
 1016         (a)At any time, if the health maintenance organization
 1017  verified the eligibility of an insured at the time of treatment
 1018  and provided an authorization number.
 1019         (b) More than 1 year after the date of payment of the
 1020  claim.
 1021         Section 24. Section 641.393, Florida Statutes, is created
 1022  to read:
 1023         641.393Fail-first protocols.—If medication for the
 1024  treatment of a medical condition is restricted for use by a
 1025  health maintenance organization through a step-therapy or fail
 1026  first protocol, the prescribing provider shall have access to a
 1027  clear and convenient process to request an override of such
 1028  restriction from the organization. The health maintenance
 1029  organization shall grant an override of the protocol within 24
 1030  hours under the following circumstances:
 1031         (1) The prescribing provider determines, based on sound
 1032  clinical evidence, that the preferred treatment required under
 1033  step-therapy or fail-first protocol has been ineffective in the
 1034  treatment of the subscriber’s disease or medical condition; or
 1035         (2) The prescribing provider believes, based on sound
 1036  clinical evidence or medical and scientific evidence, that the
 1037  preferred treatment required under the step-therapy or fail
 1038  first protocol:
 1039         (a) Is expected to, or is likely to, be ineffective given
 1040  the known relevant physical or mental characteristics and
 1041  medical history of the subscriber and the known characteristics
 1042  of the drug regimen; or
 1043         (b) Will cause, or is likely to cause, an adverse reaction
 1044  or other physical harm to the subscriber.
 1045         (3) If the prescribing provider allows the subscriber to
 1046  enter the step-therapy or fail-first protocol recommended by the
 1047  health maintenance organization, the duration of the step
 1048  therapy or fail-first protocol may not exceed a period deemed
 1049  appropriate by the provider. If the prescribing provider deems
 1050  the treatment clinically ineffective, the subscriber is entitled
 1051  to receive the recommended course of therapy without requiring
 1052  the prescribing provider to seek approval for an override of the
 1053  step-therapy or fail-first protocol.
 1054         Section 25. Subsection (21) of section 893.02, Florida
 1055  Statutes, is amended to read:
 1056         893.02 Definitions.—The following words and phrases as used
 1057  in this chapter shall have the following meanings, unless the
 1058  context otherwise requires:
 1059         (21) “Practitioner” means a physician licensed under
 1060  pursuant to chapter 458, a dentist licensed under pursuant to
 1061  chapter 466, a veterinarian licensed under pursuant to chapter
 1062  474, an osteopathic physician licensed under pursuant to chapter
 1063  459, an advanced registered nurse practitioner certified under
 1064  chapter 464, a naturopath licensed under pursuant to chapter
 1065  462, a certified optometrist licensed under pursuant to chapter
 1066  463, or a podiatric physician licensed under pursuant to chapter
 1067  461, or a physician assistant licensed under chapter 458 or
 1068  chapter 459, provided such practitioner holds a valid federal
 1069  controlled substance registry number.
 1070         Section 26. Paragraph (n) of subsection (1) of section
 1071  948.03, Florida Statutes, is amended to read:
 1072         948.03 Terms and conditions of probation.—
 1073         (1) The court shall determine the terms and conditions of
 1074  probation. Conditions specified in this section do not require
 1075  oral pronouncement at the time of sentencing and may be
 1076  considered standard conditions of probation. These conditions
 1077  may include among them the following, that the probationer or
 1078  offender in community control shall:
 1079         (n) Be prohibited from using intoxicants to excess or
 1080  possessing any drugs or narcotics unless prescribed by a
 1081  physician, advanced registered nurse practitioner, or physician
 1082  assistant. The probationer or community controllee may shall not
 1083  knowingly visit places where intoxicants, drugs, or other
 1084  dangerous substances are unlawfully sold, dispensed, or used.
 1085         Section 27. Paragraph (a) of subsection (1) and subsection
 1086  (2) of section 458.348, Florida Statutes, are amended to read:
 1087         458.348 Formal supervisory relationships, standing orders,
 1088  and established protocols; notice; standards.—
 1089         (1) NOTICE.—
 1090         (a) When a physician enters into a formal supervisory
 1091  relationship or standing orders with an emergency medical
 1092  technician or paramedic licensed pursuant to s. 401.27, which
 1093  relationship or orders contemplate the performance of medical
 1094  acts, or when a physician enters into an established protocol
 1095  with an advanced registered nurse practitioner, which protocol
 1096  contemplates the performance of medical acts identified and
 1097  approved by the joint committee pursuant to s. 464.003(2) or
 1098  acts set forth in s. 464.012(3) and (4), the physician shall
 1099  submit notice to the board. The notice shall contain a statement
 1100  in substantially the following form:
 1101  
 1102         I, ...(name and professional license number of
 1103  physician)..., of ...(address of physician)... have hereby
 1104  entered into a formal supervisory relationship, standing orders,
 1105  or an established protocol with ...(number of persons)...
 1106  emergency medical technician(s), ...(number of persons)...
 1107  paramedic(s), or ...(number of persons)... advanced registered
 1108  nurse practitioner(s).
 1109  
 1110         (2) ESTABLISHMENT OF STANDARDS BY JOINT COMMITTEE.—The
 1111  joint committee created under s. 464.003(2) shall determine
 1112  minimum standards for the content of established protocols
 1113  pursuant to which an advanced registered nurse practitioner may
 1114  perform medical acts identified and approved by the joint
 1115  committee pursuant to s. 464.003(2) or acts set forth in s.
 1116  464.012(3) and (4) and shall determine minimum standards for
 1117  supervision of such acts by the physician, unless the joint
 1118  committee determines that any act set forth in s. 464.012(3) or
 1119  (4) is not a medical act. Such standards shall be based on risk
 1120  to the patient and acceptable standards of medical care and
 1121  shall take into account the special problems of medically
 1122  underserved areas. The standards developed by the joint
 1123  committee shall be adopted as rules by the Board of Nursing and
 1124  the Board of Medicine for purposes of carrying out their
 1125  responsibilities pursuant to part I of chapter 464 and this
 1126  chapter, respectively, but neither board shall have disciplinary
 1127  powers over the licensees of the other board.
 1128         Section 28. Paragraph (a) of subsection (1) of section
 1129  459.025, Florida Statutes, is amended to read:
 1130         459.025 Formal supervisory relationships, standing orders,
 1131  and established protocols; notice; standards.—
 1132         (1) NOTICE.—
 1133         (a) When an osteopathic physician enters into a formal
 1134  supervisory relationship or standing orders with an emergency
 1135  medical technician or paramedic licensed pursuant to s. 401.27,
 1136  which relationship or orders contemplate the performance of
 1137  medical acts, or when an osteopathic physician enters into an
 1138  established protocol with an advanced registered nurse
 1139  practitioner, which protocol contemplates the performance of
 1140  medical acts identified and approved by the joint committee
 1141  pursuant to s. 464.003(2) or acts set forth in s. 464.012(3) and
 1142  (4), the osteopathic physician shall submit notice to the board.
 1143  The notice must contain a statement in substantially the
 1144  following form:
 1145  
 1146         I, ...(name and professional license number of osteopathic
 1147  physician)..., of ...(address of osteopathic physician)... have
 1148  hereby entered into a formal supervisory relationship, standing
 1149  orders, or an established protocol with ...(number of
 1150  persons)... emergency medical technician(s), ...(number of
 1151  persons)... paramedic(s), or ...(number of persons)... advanced
 1152  registered nurse practitioner(s).
 1153         Section 29. Subsection (10) of s. 458.331, paragraph (g) of
 1154  subsection (7) of s. 458.347, subsection (10) of s. 459.015,
 1155  paragraph (f) of subsection (7) of s. 459.022, and paragraph (b)
 1156  of subsection (5) of s. 465.0158, Florida Statutes, are
 1157  reenacted for the purpose of incorporating the amendment made by
 1158  this act to s. 456.072, Florida Statutes, in references thereto.
 1159         Section 30. Paragraph (mm) of subsection (1) of s. 456.072
 1160  and s. 466.02751, Florida Statutes, are reenacted for the
 1161  purpose of incorporating the amendment made by this act to s.
 1162  456.44, Florida Statutes, in references thereto.
 1163         Section 31. Section 458.303, paragraph (b) of subsection
 1164  (7) of s. 458.3475, paragraph (e) of subsection (4) and
 1165  paragraph (c) of subsection (9) of s. 459.022, and paragraph (b)
 1166  of subsection (7) of s. 459.023, Florida Statutes, are reenacted
 1167  for the purpose of incorporating the amendment made by this act
 1168  to s. 458.347, Florida Statutes, in references thereto.
 1169         Section 32. Paragraph (c) of subsection (3) of s. 464.012,
 1170  Florida Statutes, is reenacted for the purpose of incorporating
 1171  the amendment made by this act to s. 464.003, Florida Statutes,
 1172  in a reference thereto.
 1173         Section 33. Paragraph (a) of subsection (1) of s. 456.041,
 1174  subsections (1) and (2) of s. 458.348, and subsection (1) of s.
 1175  459.025, Florida Statutes, are reenacted for the purpose of
 1176  incorporating the amendment made by this act to s. 464.012,
 1177  Florida Statutes, in references thereto.
 1178         Section 34. Subsection (7) of s. 464.0205, Florida
 1179  Statutes, is reenacted for the purpose of incorporating the
 1180  amendment made by this act to s. 464.013, Florida Statutes, in a
 1181  reference thereto.
 1182         Section 35. Subsection (11) of s. 320.0848, subsection (2)
 1183  of s. 464.008, subsection (5) of s. 464.009, and paragraph (b)
 1184  of subsection (1), subsection (3), and paragraph (b) of
 1185  subsection (4) of s. 464.0205, Florida Statutes, are reenacted
 1186  for the purpose of incorporating the amendment made by this act
 1187  to s. 464.018, Florida Statutes, in references thereto.
 1188         Section 36. Section 775.051, Florida Statutes, is reenacted
 1189  for the purpose of incorporating the amendment made by this act
 1190  to s. 893.02, Florida Statutes, in a reference thereto.
 1191         Section 37. Paragraph (a) of subsection (3) of s. 944.17,
 1192  subsection (8) of s. 948.001, and paragraph (e) of subsection
 1193  (1) of s. 948.101, Florida Statutes, are reenacted for the
 1194  purpose of incorporating the amendment made by this act to s.
 1195  948.03, Florida Statutes, in references thereto.
 1196         Section 38. Except as otherwise expressly provided in this
 1197  act, this act shall take effect upon becoming a law.